Vetiqure would like to thank its customers, distributors and partners for a successful first half of the year!

After an intensive first six months, we proclaim that we have made great clinical and commercial progress in the establishment of our unique Tumour Specific Electroporation technology (TSE) on the veterinary market in Europe, Australia as well as in the USA.

Following installations of TSE, after thorough evaluations, at leading universities in the UK, Turkey, and Australia, we have now also established customer relations with some of USA's and Scandinavia's largest players in veterinary healthcare. This is not only a seal of quality, but of course will create opportunities to build long-term and strong relationships for both mutual clinical and commercial interests.

Within the framework of the TSE study at Istanbul University Cerrahpasa Veterinary, where our distributor Hasvet has installed a vetIQure, they have until today treated approximately 20 patients, many of whom responded very well to the treatment.

On the same theme, the studies on horses also continue in Australia, where we have previously communicated a first order for a vetIQure system, via our distributor Gamma Gurus. We see great potential to reach out to many more following this and future studies.

We will continue to focus on and ensure that you as customers can gradually increase the number of treatments, as your clinical experience becomes greater and greater. We will also place great emphasis on expanding production capacity to ensure good delivery times for both vetIQure systems and treatment kits.

This spring, we started testing on two of our newest R&D projects along with our CoE (Centre of Excellence) in the USA as well as at the clinics that have expressed their interest in becoming a CoE during the next six months.

In our effort to improve our marketing communications, we recently launched our new website for Vetiqure. Please go and look around: www.vetiqure.com.

We here at Vetiqure together with our subsidiary VQ Animal Care Inc. in the USA would like to thank everyone for their shown interest and commitment and we look forward to continuing working with you to further help cure, reduce the costs, risks and suffering of many more patients.

Kind regards

Vetiqure's global team

For further information please contact:

Mohan Frick, CEO

Phone: +46 (0)10-218 93 00

E-mail: ir@chemotech.se

Scandinavian ChemoTech AB (publ)

ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Redeye AB is the company's Certified Adviser. Read more at: www.chemotech.se.